IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

 

Notes

 

01.01.–30.09.2022

 

01.01.–30.09.2021

 

01.07.–30.09.2022

 

01.07.–30.09.2021

Operating income

 

 

 

 

 

 

 

 

 

 

Net gains from securities

 

4

 

 

187 170

 

220 509

 

Foreign exchange gains

 

 

 

1 258

 

 

478

 

Other income

 

 

 

4

 

4

 

1

 

 

 

 

 

1 262

 

187 174

 

220 988

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Net losses from securities

 

4

 

(290 136)

 

 

 

(192 643)

Finance expenses

 

 

 

(949)

 

(648)

 

(358)

 

(251)

Foreign exchange losses

 

 

 

 

(623)

 

 

(149)

Administrative expenses

 

7

 

(29 269)

 

(39 806)

 

(9 369)

 

(13 821)

Other expenses

 

 

 

(3 498)

 

(4 943)

 

(964)

 

(1 515)

 

 

 

 

(323 852)

 

(46 020)

 

(10 691)

 

(208 379)

Profit/(loss) before tax

 

8

 

(322 590)

 

141 154

 

210 297

 

(208 379)

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(58)

 

(57)

 

(19)

 

(19)

Profit/(loss) for the period

 

 

 

(322 648)

 

141 097

 

210 278

 

(208 398)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(322 648)

 

141 097

 

210 278

 

(208 398)

 

 

 

 

 

 

 

 

 

 

 

Income per share in CHF

 

9

 

(5.86)

 

2.55

 

3.83

 

(3.76)

Diluted income per share in CHF

 

9

 

(5.86)

 

2.55

 

3.83

 

(3.76)

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer